Roche: subcutaneous breast cancer drugs efficient
(CercleFinance.com) - Subcutaneous injection of Roche's Perjeta and Herceptin proved to be comparable to intravenous formulations in people with HER2-positive breast cancer, the Swiss drugmaker said on Thursday.
New data from a phase III study showed the investigational fixed-dose combination of Perjeta and Herceptin administered by subcutaneous injection, in combination with chemotherapy, demonstrated comparable efficacy and safety to standard infusions of the targeted antibodies and chemotherapy in people with HER2-positive early breast cancer.
Subcutaneous administration of the drugs takes approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose, compared to approximately 150 minutes for the standard formulations.
Data will now be submitted to health authorities globally, Roche said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
New data from a phase III study showed the investigational fixed-dose combination of Perjeta and Herceptin administered by subcutaneous injection, in combination with chemotherapy, demonstrated comparable efficacy and safety to standard infusions of the targeted antibodies and chemotherapy in people with HER2-positive early breast cancer.
Subcutaneous administration of the drugs takes approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose, compared to approximately 150 minutes for the standard formulations.
Data will now be submitted to health authorities globally, Roche said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.